SystImmune Inc. Report issue

For profit Phase 1
Founded: Richmond WA United States (2014)

Organization Overview

First Clinical Trial
2020
NCT04603287
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

SystImmune Inc.